Showing 2451-2460 of 5644 results for "".
- US Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucomahttps://modernod.com/news/us-patent-office-issues-notice-of-allowance-for-nicoxs-latanoprostene-bunod-in-normal-tension-glaucoma/2479119/Nicoy announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma. Latanoprostene bunod ophthalmic solution, 0.024%, is commercialized as Vyzulta for
- Amydis Completes Pre-IND Meeting With the FDA for the Development of a Retinal Tracer for the Diagnosis of Alpha-Synucleinopathieshttps://modernod.com/news/amydis-completes-pre-ind-meeting-with-the-fda-for-the-development-of-a-retinal-tracer-for-the-diagnosis-of-alpha-synucleinopathies/2479113/Amydis announced completion of pre-Investigational New Drug (IND) interaction with the FDA regarding the current development plan for a small-molecule retinal tracer for the diagnosis of α-synucleinopathies (ASYN). Funding provided by The Michael J. Fox Foundation for Parkinson’s
- Market Scope: US Cataract Pharmaceuticals Evolve in Drug Deliveryhttps://modernod.com/news/market-scope-us-cataract-pharmaceuticals-evolve-in-drug-delivery/2479107/US cataract surgeons showed a preference for incremental improvement in drug delivery over revolutionary change in the first full year for three new corticosteroid products to manage inflammation and pain after cataract surgery, according to a Market Scope report. The products hit the mark
- RETINA-AI Health Awarded US Patent for AI Detection of Eye Diseasehttps://modernod.com/news/retina-ai-health-awarded-us-patent-for-ai-detection-of-eye-disease/2479088/RETINA-AI Health has been awarded a US patent on its artificial intelligence (AI) systems for autonomous detection of eye diseases from images. There are several eye diseases such as diabetic retinopathy, macular degeneration, and glaucoma for which segments of the general population need to be r
- ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat DED & Ocular Inflammationhttps://modernod.com/news/protokinetix-engages-multi-national-partner-for-formulation-of-topical-drug-to-treat-ded-ocular-inflammation/2479083/ProtoKinetix announced that it has engaged a global pharmaceutical company to develop the formulation as a topical ocular drug for the treatment of dry eye disease (DED) and ocular inflammation using AAGP. For the development of this drug for DED to date the company has completed:
- Lantronix Contributes to eSight Design, Enabling Individuals With Serious Visual Impairment to Seehttps://modernod.com/news/lantronix-contributes-to-esight-design-enabling-individuals-with-serious-visual-impairment-to-see/2479082/Lantronix announced that its engineering services team supported eSight Corp. in the development of an enhanced vision device that enables individuals with serious visual impairment to see. eSight was recently recognized as a manufacturer of the Best Wearable/Healthcare Hardware/Soft
- Bausch + Lomb Announces Topline Results From The First Phase 3 Trial Of NOV03 In Dry Eye Disease Associated With MGDhttps://modernod.com/news/bausch-lomb-announces-topline-results-from-the-first-phase-3-trial-of-nov03-in-dry-eye-disease-associated-with-mgd/2479072/Bausch + Lomb and Novaliq announced statistically significant topline data from the first phase 3 trial (GOBI trial) evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (D
- NEI Joins Call for Standardization of Ophthalmic Imaging Deviceshttps://modernod.com/news/nei-joins-call-for-standardization-of-ophthalmic-imaging-devices/2479064/The National Eye Institute (NEI), part of the National Institutes of Health, is joining the American Academy of Ophthalmology (AAO) and others in calling for imaging device makers to standardize their data formatting. Such standardization is expected to enable comm
- FDA Approves Bausch + Lomb ClearVisc Dispersive Ophthalmic Viscosurgical Device (OVD)https://modernod.com/news/fda-approves-bausch-lomb-clearvisc-dispersive-ophthalmic-viscosurgical-device-ovd/2479058/Bausch + Lomb, announced that the FDA has approved ClearVisc dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery. “OVDs play a critical role in ophthalmic surgery, and ClearVisc offers surgeons unique advantages that are designed to contribute to surgical safety
- Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directorshttps://modernod.com/news/second-sight-medical-products-names-dean-baker-and-alexandra-larson-to-its-board-of-directors/2479051/Second Sight Medical Products announced that the company’s Board of Directors has appointed two new members, Dean Baker, PhD, and Alexandra Larson. Dr. Baker has also been appointed to the Audit Committee of the Board. “We are honored and excited to add these two very talented individuals